Human Reproductive Technologies Market

Human Reproductive Technologies Market, By Technology (Infertility Drugs and Contraceptive Drugs and Devices), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2023 - 2030

Human reproductive technologies assist parents who are having troubles in pregnancies, and infertility issues. These technologies include Assisted Reproductive Technology (ART), prognostics, contraception, and same-sex procreation. ART aids in the treatment of low fertility or infertility using artificial insemination, artificial reproduction, cloning, cytoplasmic transfer, fertility medication, hormone treatment, and others. The second most common reason for using assisted reproductive technology is infertility. IVF completely omits the fallopian tubes for treating patients with tubal factor infertility. Male factor infertility, decreased ovarian reserve, ovarian failure (with donor eggs), ovulatory dysfunction, and unexplained infertility are among other infertility etiologies that can be treated with IVF. IVF can be utilized with a gestational carrier in patients for whom pregnancy is generally contraindicated (described below) or with uterine factor infertility. IVF is also used outside of infertility settings. It can be used in patients desiring preimplantation genetic testing before conception (such as those known to be carriers of certain genetic disorders), fertility preservation, such as prior to gonadotoxic therapy, or in patients desiring to delay childbearing. These women can opt to freeze their eggs or embryos if they are in a stable relationship. The high prevalence of maternal mortality, increasing population and increasing focus on family planning is expected to boost the global human reproductive technologies market over the forecast period.

Market Dynamics

The high prevalence of maternal mortality and increasing population had assisted the key players to focus on various growth strategies for the product launch as well as acquisitions, which will lead to the growth of global human reproductive technologies market over the forecast period. For instance, in May 2022, Perrigo Company plc., a provider of Consumer Self-Care Products, announced that it completed the acquisition of HRA Pharma, a global independent pharmaceutical company that engineers and commercializes drugs in the women's health and endocrinology segments. for US$ 1.9 billion based on current exchange rates, in cash, accelerating its position as a global consumer self-care company.

Key features of the study:

• This report provides in-depth analysis of the global human reproductive technologies market, and provides market size (US$ Billion) and Compound Annual Growth Rate (CAGR%) for the forecast period (2023–2030), considering 2022 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global human reproductive technologies market based on the following parameters– company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study are Abbott, Evofem Biosciences, Inc., Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Perrigo Company plc., Uniprix, Lupin, Sandoz International GmbH, Aurobindo Pharma, Bayer AG, Lilly, GSK plc., Mankind Pharma, Church & Dwight Co., Inc., and Pfizer, Inc.
• Insights from this report will allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• Global human reproductive technologies market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global human reproductive technologies market

Detailed Segmentation:

• Global Human Reproductive Technologies Market, By Technology:
• Infertility Drugs
• Contraceptive Drugs and Devices
• Global Human Reproductive Technologies Market, By Region:
• North America
• U.S.
• Canada
• Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Russia
• Rest of Europe
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• ASEAN
• Rest of Asia Pacific
• Middle East
• GCC
• Israel
• Rest of Middle East
• Africa
• South Africa
• Central Africa
• North Africa
• Company Profiles
• Abbott
• Evofem Biosciences, Inc.
• Teva Pharmaceutical Industries Ltd.
• Sun Pharmaceutical Industries Ltd.
• Perrigo Company plc.
• Uniprix
• Lupin
• Sandoz International GmbH
• Aurobindo Pharma
• Bayer AG
• Lilly
• GSK plc.
• Mankind Pharma
• Church & Dwight Co., Inc.
• Pfizer, Inc.